best practice:- Special Edition Contents

Special Edition March 2007 - Contents

Welcome to this special edition of best practice journal which has been produced as part of an education programme for community pharmacists to support the paroxetine brand change.

An abridged version of the original welcome letter can be found here.

Back to the Paroxetine switch home page

Depression - causes, presentation and treatment overview

Select

Depression is common, serious and treatable
Multifactorial causes
Presentations vary
Treatment
Mechanism of action
Choosing an antidepressant

Optimising response
Appropriate dose and duration
Changing drug therapy
Getting well, staying well
Interventions in the pharmacy
References

Key messages on the use of SSRIs

Select

Key messages
SSRIs have other indications

What is bioequivalence

Select

What is bioequivalence?
bioequivalence of Loxamine vs Aropax

Mental Health Foundation

Select

Making mental health everybody’s business
Mental Health Foundation key services

Drug interactions with antidepressants

Select

Introduction
Table 1: Some important drug interactions with antidepressants
Table 2: Some important drug interactions with tricyclic antidepressants

The CYP450 system

Select

The CYP450 System
Examples
Table 1: Main metabolic pathways of commonly prescribed antidepressants

Changing to a generic drug

Select

Changing to a generic drug
SSRI antidepressants and brand changing
How do patients perceive the risk of changing to a generic drug?
Patient information programmes make brand changing easier
References

Counselling patients through a brand change

Select

Accentuate the positive...
3 key questions and possible answers
Culture and communication